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B R I E F  R E P O R T
Patterns of Tumor Necrosis Factor Inhibitor (TNFi) 
Biosimilar Use Across United States Rheumatology 
Practices
Nick Bansback,1 Jeffrey R. Curtis,2  Jie Huang,3 Zeling He,3 Michael Evans,4 Tracy Johansson,5  
Kaleb Michaud,6  Gabriela Schmajuk,7  and Katherine P. Liao8
Objective. It is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase 
competition and improve accessibility. This study evaluates biosimilar tumor necrosis factor inhibitor (TNFi) utilization 
across rheumatology practices in the United States and compares whether patients initiating biosimilars remain on 
these treatments at least as long as new initiators of bio-originators.
Methods. We identified a cohort of patients initiating a TNFi biosimilar between January 2017 and September 
2018 from an electronic health record registry containing data from 218 rheumatology practices and over 1 million 
rheumatology patients in the United States. We also identified a cohort of patients who initiated the bio-originator 
TNFi during the same period. We calculated the proportion of biosimilar prescriptions compared with other TNFi’s 
and compared persistence on these therapies, adjusting for age, sex, diagnoses codes, and insurance type.
Results. We identified 909 patients prescribed the biosimilar infliximab-dyyb, the only biosimilar prescribed, and 
4413 patients with a new prescription for the bio-originator infliximab. Biosimilar patients tended to be older, have a 
diagnosis code for rheumatoid arthritis, and covered by Medicare insurance. Over the study period, biosimilar pre-
scriptions reached a maximum of 3.5% of all TNFi prescriptions. Patients persisted on the biosimilar at least as long 
as the bio-originator infliximab (hazard ratio [HR] 0.83, P = 0.07).
Conclusion. The uptake of biosimilars in the United States remains low despite persistence on infliximab-dyyb 
being similar to the infliximab bio-originator. These results add to clinical studies that should provide greater confi-
dence to patients and physicians regarding biosimilar use.
INTRODUCTION
Biosimilars of biologics, specifically tumor necrosis factor inhibi-
tors (TNFis) for inflammatory conditions such as rheumatoid arthritis 
(RA), psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis 
(AS) entered the US market in 2016. Biosimilars are biological prod-
ucts that are “highly similar to the reference product notwithstand-
ing minor differences in clinically inactive components.” One hope 
for biosimilars was that they would lower the cost of TNFi therapy, 
increase competition, and improve accessibility for patients. Prior to 
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US Federal Drug Administration (FDA) approval, extensive analytical 
and clinical studies comparing each biosimilar to its bio-originator to 
confirm “no clinical meaningful differences” were required. Whether 
they have been widely adopted remains to be seen as there are 
limited data on biosimilar utilization in the United States.
Because biosimilars for rheumatic conditions are relatively 
new to the US market, a study population comparing sufficient 
patients prescribed biosimilars can be difficult to obtain even 
within a large health care system, as rheumatology patients tend 
to be a small percentage of any overall patient population. Rheu-
matology-specific electronic health record (EHR) data registries, 
such as the American College of Rheumatology (ACR) Rheuma-
tology Informatics System for Effectiveness (RISE) (1), could facil-
itate the ability to examine the early utilization of new rheumatic 
disease–specific therapies, such as TNFi biosimilars.
The objective of this study was to evaluate early biosimilar 
TNFi utilization in the United States and to measure persistence of 
biosimilars compared with their bio-originator as a proxy for both 
effectiveness and safety of treatment.
MATERIALS AND METHODS
Data source. The RISE registry contains EHR data from 
approximately 218 rheumatology practices and over 1 million 
unique rheumatology patients (1). The EHR data in RISE were col-
lected passively with the primary purpose to assist participating 
practices with national quality reporting requirements. These data 
also serve as a platform for studies on quality reporting and health 
care utilization consisting mainly of group and private practices 
across the United States.
Study period. To determine the starting month and year 
for analysis, we searched for the first biosimilar prescription in the 
RISE data set using medication codes and string searches for 
the available biosimilars in the US market. These included inflixi-
mab-dyyb or “Inflectra” (launched in the United States in Novem-
ber 2016) and infliximab-abda or “Renflexis” (launched in July 
2017). We identified that the first biosimilar prescribed for any 
patient in RISE was infliximab-dyyb in January 2017. There were 
no data available for other biosimilars during our study period in 
the RISE data set.
Patients. We identified a cohort of patients who initiated a 
biosimilar in the time period from January 2017 through Septem-
ber 2018. We also identified a cohort of patients who initiated the 
bio-originator infliximab or “Remicade” during the same period. New 
users of infliximab were defined as patients initiating infliximab at 
or after the date of the first biosimilar prescription in January 2017 
and had no biosimilar or bio-originator infliximab prescriptions or 
infusions in the 3 months prior. Patients who initiated infliximab but 
switched to the biosimilar during the study period were included only 
in the biosimilar group, thus their time zero begins at the start of the 
biosimilar. All subjects were followed until they were either prescribed 
another biologic disease-modifying antirheumatic drug (DMARD) or 
to their last follow-up date in the EHR, whichever came first.
Covariates. We extracted information on patient age, sex, 
race, insurance type (Medicare, Medicaid, commercial), geo-
graphic location (region), diagnoses codes (International Classifi-
cation of Diseases 9th and 10th revision), and prior drug utilization 
from RISE. Specifically, we examined utilization of either biologic 
or nonbiologic DMARD use in the 3 months prior to starting the 
biosimilar or infliximab.
Analysis. To assess biosimilar utilization across RISE prac-
tices, we calculated the proportion of biosimilar prescriptions 
compared with other TNFis each month from January 2017, the 
month of the first biosimilar prescription, to September 2018, the 
last month for follow-up in this study.
Among new initiators of the biosimilar and bio-originator 
infliximab, baseline demographic data were compared between 
the two groups. Persistence on the biosimilar was compared with 
new initiators of infliximab and defined as a new prescription for 
either the biosimilar or infliximab; all patients must have had at 
least 12 weeks of follow-up time in the RISE data (defined by the 
last observation available) and no new prescription for another 
biologic DMARD. Data on persistence between the biosimilar and 
infliximab were compared using Kaplan-Meier curves. As a sen-
sitivity analysis, we constructed Kaplan-Meier curves for patients 
with 2 or more consecutive prescriptions of either the biosimilar 
or infliximab, and persistence was defined as above, with 12 or 
more weeks of follow-up time after the second prescription. As in 
the main analysis, patients who filled or received another biologic 
DMARD in the follow-up period were considered nonpersistent.
Cox proportional hazards regression analysis was conducted 
to examine the influence of biosimilar versus infliximab utilization on 
persistence, adjusting for age, sex, and diagnosis codes—factors 
that differed between those initiating a biosimilar versus infliximab.
Analyses were performed using R (v.3.4.4). The RISE registry 
was reviewed by the Western Institutional Review Board and has 
SIGNIFICANCE & INNOVATIONS
• Among TNFi biosimilar prescriptions, only inflix-
imab-dyyb has been prescribed, comprising of a 
maximum of 3.5% of all TNFi prescriptions, with the 
majority of new initiators previously being on the 
bio-originator infliximab.
• Patients remain on the biosimilar infliximab-dyyb 
for a similar amount of time as the bio-originator 
infliximab.
• Merging electronic health record data from hun-
dreds of rheumatology practices into one registry 
enables early studies of new treatment options in 
rheumatology, such as biosimilars.
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been designated as a quality improvement registry allowing for 
studies on health care utilization using a limited data set without 
individual patient consent.
RESULTS
We identified 909 patients who were prescribed the biosimilar 
infliximab-dyyb and 4,413 patients with a new prescription for the 
bio-originator infliximab in the period from January 2017 through 
September 2018. No other biosimilar prescriptions were identified 
in the registry during the study period. Overall, biosimilar prescrip-
tions reached a maximum of 3.5% of all TNFi prescriptions during 
the study period, contributing to 17% of new infliximab-based pre-
scriptions. Patients prescribed biosimilars tended to be older, have 
a diagnosis code for RA, and were covered by Medicare insurance 
(Table 1). The region with the most biosimilar prescriptions was the 
South Atlantic, comprising 25.8% of all biosimilars in RISE, and the 
region with the fewest prescriptions being New England. Although 
New England was one of the regions with the least number of 
practices in the RISE registry—and the South Atlantic had the 
most—there was no correlation between number of practices per 
region and biosimilar prescriptions. The Mid-Atlantic region com-
prised 17.8% of RISE practices, second only to the South Atlan-
tic in the number of practices. However, it was the third lowest 
Table 1. Patient characteristics at baseline, prior to initiating infliximab-dyyb or infliximab
Clinical Characteristics
Infliximab-dyyb,  
n = 909
Infliximab,  
n = 4329 P Value
Age, mean (yrs) 64.9 (13.4) 57.5 (14.3) <0.001
Female, % 647 (71.18%) 3361 (73.02%) 0.276
Self-reported race, n (%)a   <0.001
White 680 (83.54%) 2475 (75.05%)  
Black 36 (4.42%) 303 (9.19%)  
Other 98 (12.04%) 520 (15.77%)  
Diagnosis codes, n (%)    
Rheumatoid arthritis 536 (58.97%) 2192 (49.67%) <0.001
Psoriasis or psoriatic arthritis 177 (19.47%) 699 (15.84%) 0.008
Ankylosing spondylitis 51 (5.61%) 341 (7.73%) 0.0031
bDMARDs, n (%)    
Any TNFi 703 (77.34%) 934 (21.16%) <0.001
Adalimumab 77 (8.47%) 919 (21.23%) <0.001
Certolizumab 32 (3.52%) 224 (5.17%) 0.042
Etanercept 48 (5.28%) 510 (11.78%) <0.001
Golimumab 24 (2.64%) 181 (4.1%) 0.047
Infliximab 522 (57.43%) 0 …
Abatacept 30 (3.3%) 181 (4.18%) 0.238
Rituximab 9 (0.99%) 47 (1.09%) 0.841
Tocilizumab 17 (1.87%) 147 (3.4%) 0.018
Tofacitinib 26 (2.86%) 127 (2.93%) 0.975
Nonbiologic DMARDb 37 (4.07%) 132 (3.05%) 0.069
No prior DMARD information 124 (13.64%) 1995 (46.08%) <0.001
Type of insurance, n (%)c   <0.001
Medicare 352 (69.84%) 827 (40.96%)  
Medicaid 10 (1.98%) 97 (4.80%)  
Commercial 142 (28.17%) 1095 (54.23%)  
Geographic regiond   <0.001
New England 3 (0.33%) 93 (2.14%)  
Mid-Atlantic 37 (4.07%) 821 (19.0%)  
East North Central 126 (13.86%) 742 (17.14%)  
West North Central 8 (0.88%) 399 (9.22%)  
South Atlantic 228 (25.8%) 996 (23.01%)  
East South Central 108 (11.88%) 337 (7.78%)  
West South Central 118 (12.98%) 377 (8.71%)  
Mountain 95 (10.45%) 315 (7.28%)  
Pacific 186 (20.46%) 249 (5.75%)  
Abbreviation: bDMARD, biologic disease-modifying antirheumatic drug; TNFi, tumor necro-
sis factor inhibitor.
aAvailable in n = 822 biosimilar and n = 3298 in infliximab.
bNonbiologic DMARD = methotrexate, hydroxychloroquine, leflunomide, and sulfasalazine. 
cAvailable on n = 504 biosimilar and n = 2019 infliximab. 
dGeographic regions: New England: ME, MA, CT, VT, NH, RI; Mid-Atlantic: MD, PA, VA, NJ, NY, 
NM, DC, WV; East North Center: KS, IA, MN, MO, NE, ND, SD; South Atlantic: NC, SC, GA, FL; 
East South Central: AL, KY, MS, TN; West South Central: AK, LA, OK, TX; Mountain: CO, AZ, UT, 
NM, ID, MT, WY; Pacific: AL, CA, HI, OR, WA. 
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prescriber of the biosimilar. Nearly 60% of patients on the biosimi-
lar were using infliximab prior to switching to infliximab-dyyb.
Although crude persistence to biosimilar infliximab-dyyb was 
greater than infliximab (80% vs 75%, P = 0.02) at 20 months fol-
low-up (Figure 1), the clinical difference was relatively small. In the 
sensitivity analysis, which was restricted to patients with at least 
two consecutive prescriptions for the biosimilar or infliximab, we 
observed a similar small difference in persistence of 5% with a 
higher percentage persisting on biosimilars (P = 0.02). The results 
of the multivariate Cox proportional hazards model are shown in 
Table 2. After adjusting for the potential confounding variables, we 
observed no statistically significant difference in persistence with 
treatment between the two groups; the HR for nonpersistence 
was 0.83 (P = 0.07) in biosimilar-dyyb compared with infliximab.
DISCUSSION
This study describes the uptake of biosimilars in patients with 
inflammatory disease using real-world data from rheumatology prac-
tices across the United States. Despite the promise of lower prices 
and increasing data on the equivalent safety and efficacy from clin-
ical trials (2), the uptake of biosimilars in the United States remains 
low; nearly 2 years after market entry, only 3.5% among rheumatol-
ogy practices have participated in the RISE registry. Furthermore, we 
observed that persistence on infliximab-dyyb was similar to inflixi-
mab, further allaying concerns over the use of biosimilars even after 
adjusting for potential differences between the groups.
The uptake of biosimilars in this study contrasts with that in 
other countries. In Asia, biosimilar use within the first year was 
greater than 10% (3). A study in Sweden showed that the uptake 
of biosimilars was over 30% by the end of 2016 (4). There are 
various plausible reasons for the low uptake of biosimilars in the 
United States. Potential causes include mistrust from patients or 
physicians about the equivalence between biosimilars and their 
originator (5). Some of this mistrust has been facilitated by unfa-
miliarity with biosimilars, misinformation, and lobbying (6). Com-
plexities with regard to pricing also mean the savings realized in 
other countries (7) may not be seen in the United States (8). For 
Figure 1. Comparison of persistence on treatment among infliximab-dyyb to infliximab among new initiators.
Table 2. Hazard ratio among new initiators of biosimilar or infliximab for nonpersistence (switching to another bDMARD), adjusted for potential 
confounders
Clinical Characteristics
Base Model Base Model + Diagnosis
HR 95% CI P value HR 95% CI P value
Age 0.99 0.99, 1.0 0.05 0.99 0.99, 1.0 0.001
Sex 0.99 0.84, 1.2 0.91 0.92 0.78, 1.09 0.35
Race (white vs non-white) 1.18 1.0, 1.4 0.05 1.14 0.97, 1.35 0.11
Diagnoses codes (RA vs other) … … … 1.54 1.32, 1.79 <0.001
Biosimilar 0.84 0.69, 1.0 0.10 0.83 0.68, 1.01 0.07
Abbreviation: bDMARD, biologic disease-modifying antirheumatic drug; HR, hazard ratio; RA, rheumatoid arthritis.
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example, the average sales price, according to the Centers for 
Medicare & Medicaid Services, of a 100-mg vial of infliximab-dyyb 
was higher than the equivalent vial of infliximab in early 2017—
though this had reversed by the end of 2017, with biosimilar prod-
ucts becoming increasingly less expensive over time (9). At least 
for commercially insured patients, manufacturers have also alleg-
edly offered rebates on originator products to undercut biosimilar 
competition, increasing the barrier to entry for biosimilars (10). 
This might explain why, despite three infliximab biosimilars being 
approved in the US market, uptake has been slow.
The strength of our study is that we are using a large data 
set from a national US registry. Although trials of biosimilars have 
typically enrolled fewer than 600 participants, the RISE data has 
enabled us to compare nearly 1000 patients using a biosimilar to 
an originator product using real-world data (11). Limitations to this 
study include the fact that RISE may not reflect a general sampling 
of US rheumatology practices. Of the RISE practices included in 
this study, 91% were classified as solo or group practices. The 
remaining practices were classified as other clinical setting (5%), 
health system (1%), or unknown (3%). We also adjusted for a lim-
ited set of potentially confounding variables and did not include, 
for example, disease activity or obesity (body mass index). Lastly, 
we have not been able to study unexpected rare adverse events, 
though this will become possible over the longer term.
In summary, our study using real-world data suggests no 
apparent difference in patient’s persistence in biosimilar versus 
bio-originator infliximab, but despite this, it finds low biosimilar uti-
lization. This study also highlights the importance of rheumatolo-
gy-specific EHR registries that can be used to study early trends 
for new treatments that may be too uncommon to study in large 
population registries. Our findings contribute to an evidence base 
that includes existing clinical trial data, which implies that if price 
reductions can be realized, biosimilar utilization should be pro-
moted. Further policies are needed to promote fair market com-
petition and ensure accessibility to patients given the issues many 
patients have with affordability and lack of access to this speciality 
class of drugs.
ACKNOWLEDGMENTS
We would like to thank the members of the American College 
of Rheumatology Research and Publications Subcommittee for 
their general feedback on the study. Committee members not on 
the author list include: Megan Clowse, MD, MPH, Yvonne Lee, 
MD, MMSc, Esi Morgan, MD, MSCE, Andreas Reimold, MD, 
 Ankhoor Shah, MD, and Julia Simard, ScD.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it critically 
for important intellectual content, and all authors approved the final version 
to be published and take responsibility for the integrity of the data and the 
accuracy of the data analysis.
Study conception and design. Bansback, Huang, Liao.
Acquisition of data. Evans, Johansson, Schmajuk.
Analysis and interpretation of data. Bansback, Curtis, Huang, He, 
Michaud, Schmajuk, Liao.
REFERENCES
 1. Yazdany J, Bansback N, Clowse M, Collier D, Law K, Liao KP, et al. 
Rheumatology Informatics System for Effectiveness: a national infor-
matics-enabled registry for quality improvement. Arthritis Care Res 
(Hoboken) 2016;68:1866–73.
 2. Moots RJ, Curiale C, Petersel D, Rolland C, Jones H, Mysler E. Effi-
cacy and safety outcomes for originator TNF inhibitors and biosimi-
lars in rheumatoid arthritis and psoriasis trials: a systematic literature 
review. BioDrugs 2018;32:193–9.
 3. Kim SC, Choi NK, Lee J, Kwon KE, Eddings W, Sung YK, et al. Brief 
report: utilization of the first biosimilar infliximab since its approval in 
South Korea. Arthritis Rheumatol 2016;68:1076–9.
 4. Di Giuseppe D, Frisell T, Ernestam S, Forsblad-D'Elia H, Lindqvist 
E, Lindström U, et al. Uptake of rheumatology biosimilars in the ab-
sence of forced switching. Expert Opin Biol Ther 2018;18:499–504.
 5. Rezk MF, Pieper B. Treatment outcomes with biosimilars: be aware 
of the nocebo effect. Rheumatol Ther 2017;4:209–18.
 6. Brannon I. The biotech lobby fights to undermine less-costly bio-
similar drugs. URL: https ://www.forbes.com/sites/ theap othec ary/ 
2014/09/04/the-biote ch-lobby-fights-to-under mine-less-costly- 
biosi milar-drugs/ #7f891 4524595. Forbes. September 2014.
 7. Dörner T, Strand V, Cornes P, Gonçalves J, Gulácsi L, Kay J, et al. 
The changing landscape of biosimilars in rheumatology. Ann Rheum 
Dis 2016;75:974–82.
 8. Yazdany J, Dudley RA, Lin GA, Chen R, Tseng CW. Out-of-pocket 
costs for infliximab and its biosimilar for rheumatoid arthritis under 
Medicare Part D. JAMA 2018;320:931–3.
 9. Centers for Medicare and Medicaid Services. Medicare Part B drug av-
erage sales price. 2019. URL: https ://www.cms.gov/Medic are/Medic 
are-Fee-for-Servi ce-Part-B-Drugs/ McrPa rtBDr ugAvg Sales Price/ index .
 10. Grant K. How a blockbuster drug tells the story of why Canada's spend-
ing on prescriptions is sky high. URL: https ://spon.ca/how-a-block 
buster-drug-tells-the-story-of-why-canad as-spend ing-on-presc ripti 
ons-is-sky-high/2018/10/22/. Social Policty in Ontario. October 2018.
 11. Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavard-
sholm EA, et al. Switching from originator infliximab to biosimilar CT-
P13 compared with maintained treatment with originator infliximab 
(NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority 
trial. Lancet 2017;389:2304–16.
